AMCX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AMCX is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has short-term technical support, but the fundamental picture is weak, earnings expectations are falling, and analyst sentiment is mixed-to-negative. Given the user wants a direct answer and is unwilling to wait for an ideal entry, my clear opinion is to hold off on buying now.
The trend is mixed. Price closed at 8.62, just above the previous close of 8.56, and remains above the pivot at 8.388. Bullish moving averages are in place with SMA_5 > SMA_20 > SMA_200, which supports the current price structure. However, MACD histogram is -0.0322 and still below zero, showing momentum is not strongly bullish. RSI_6 at 58.63 is neutral-to-mildly positive, not oversold. Resistance is nearby at 8.678 and 8.857, so upside from here looks limited unless it breaks out decisively. Overall, the chart is mildly constructive but not a strong entry for a long-term buyer.
["SMA_5 > SMA_20 > SMA_200 indicates a supportive technical trend", "Open interest put-call ratio of 0.42 suggests bullish positioning", "Morgan Stanley raised its target from $6 to $7, which is a modest positive", "Upcoming Q1 earnings can act as a catalyst if the company beats expectations", "The Walking Dead rights reversion mentioned by Wells Fargo could create a future monetization opportunity in early 2027"]
["Q1 EPS is expected to fall 59.6% year over year", "Q1 revenue is expected to decline 2.7% year over year", "There have been five downward estimate revisions in the last three months", "2025/Q4 financials showed revenue decline, sharply lower net income, negative EPS, and weaker gross margin", "Morgan Stanley initiated coverage with an Underweight rating and a $7 target, below current price", "MACD remains negative, indicating weak momentum", "No meaningful hedge fund, insider, or congress buying support is visible"]
Latest quarter shown is 2025/Q4. Revenue fell to 594.8 million, down 0.75% year over year. Net income dropped to -55.5 million, down 80.5% YoY, and EPS dropped to -1.26, down 80.25% YoY. Gross margin also fell to 45.4, down 10.75% YoY. For the upcoming Q1 2026 season, analysts expect EPS of 0.21 versus 0.22 estimated in the calendar, and revenue of 540.32 million, down 2.7% YoY. The overall growth trend is weak and not supportive of a long-term buy thesis.
Analyst sentiment is mixed but leaning negative. Morgan Stanley assumed coverage with an Underweight rating and a $7 target, which is below the current share price and signals downside concern. Wells Fargo is more constructive, raising its target from $8 to $10 while keeping Equal Weight, citing limited upside in operations but a possible future rights-related windfall. Overall, Wall Street sees some asset value and a future catalyst, but the near-term pros and cons still lean cautious-to-negative.
